Global Genital Warts Treatment Market By Treatment Type (Physical Destruction, Chemical Destruction, Immunomodulation), By End-User (Hospitals, Specialty Clinics, Others) By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2022-2032

Genital Warts Treatment Market Introduction

The Genital Warts Treatment Market is projected to reach a valuation of USD 2,158.05 million by 2032 at a CAGR of 4.8%, from USD 1,628.9 million in 2021.

Genital warts are a Sexually Transmitted Infection (STI) caused by the Human Papillomavirus (HPV). Genital warts are soft growth that causes pain, itching, and discomfort and appears on the genitals. These growing warts are different from the high-risk strains that lead to cancer and dysplasia. HPV is the most common among all STIs. HPV infections are primarily dangerous to women because some types of HPC can cause cancer of the vulva and cervix.

Genital warts can be transmitted through sexual activities such as oral, anal, and vaginal sex. Its symptoms in some cases may not develop for several weeks or months after getting infected. Genital warts are also not always visible to the human eye, they can be small, in the same color as the skin, or sometimes slightly darker.

Genital warts resemble in shape the top of cauliflower and feel slightly bumpy or smooth to touch. Genital warts can appear on the penis, scrotum, thighs, groin, or inside or around the anus in the case of males. In females, it can appear on the inside or outside of the anus or vagina, and on the cervix.

The global genital warts treatment market is segmented on the basis of – treatment type, end-user, and region.

Detailed segmentation is as below:

By Treatment Type

• Physical Destruction
• Chemical Destruction
• Immunomodulation

By End-User

• Hospitals
• Specialty Clinics
• Others

By Region

• North America
  • The US
  • Canada
  • Mexico
• Europe
  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia-Pacific
  • China
  • Japan
  • India
  • Korea
  • Rest of Asia-Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• The Middle East and Africa
  • GCC
  • Israel
  • South Africa
  • Rest of MEA

Market Dynamics

The increasing prevalence of warts & HPV is expected to boost market growth prospects in terms of revenue for the genital warts industry. According to the Anal Cancer Foundation, approximately 14 million people are infected with HPV in the US per year. The Center for Disease Control and Prevention estimates that 340,000 to 360,000 men and women are affected by genital warts caused by HPV every year.

Moreover, the recurrence of warts increases the demand for appropriate treatment. As the infection takes weeks to develop, a large number of individuals fail to get diagnosed early. Unfortunately, a lack of awareness coupled with existing treatment procedures, which are often painful and invasive, are factors expected to hinder the market growth to a certain extent.

However, increasing awareness levels in both developed and developing nations regarding STDs (Sexually Transmitted Diseases), is another factor that is expected to bolster revenue growth prospects for the genital warts market over the forecast period.

Competitive Landscape

Major players in this market are –

• Merck & Co. Inc.
• Allergan, Bausch Health
• Lee’s Pharmaceutical Holdings Limited
• Seqirus, Sanofi
• Pfizer
• Taro Pharmaceutical Industries
• Novan Inc.
• Serum Institute of India Pvt. Ltd., among others.

For the Genital Warts Treatment Market research study, the following years have been considered to estimate the market size: